



ENLITIC

TM

Investor Presentation

7 November 2024

Important Notice and Disclaimer

This presentation has been prepared by Enlitic, Inc. (Enlitic or the Company) to provide summary information about the Company and its associated entities as at the date of this presentation, and the information in this presentation remains subject to change without notice. The Company has no obligation to update or correct this presentation.

The presentation is for informational purposes only and is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or the law of any other jurisdiction. The information contained in this presentation does not constitute investment or financial product advice (nor taxation or legal advice) and is not intended to be used as the basis for making an investment decision.

No representation or warranty, express or implied, is made as to the currency, accuracy, reliability, completeness or fairness of the information, opinions and conclusions contained in this presentation. None of the Company, its related bodies corporate (as defined in the Corporations Act), shareholders or affiliates, or any of their respective officers, directors, employees, affiliates, partners, representatives, consultants, agents or advisers (each a Limited Party) guarantees or makes any representations or warranties, express or implied, as to, or takes responsibility for, the currency, accuracy, reliability, completeness or fairness of this presentation or the information, opinions and conclusions contained in this presentation. The Company does not represent or warrant that this presentation is complete or that it contains all material information about the Company. To the maximum extent permitted by law, each Limited Party expressly disclaims any and all liability (whether direct, indirect, consequential or contingent), including, without limitation, any liability arising out of fault or negligence on the part of any person, for any expenses, damages, costs or loss arising from the use of information contained in this presentation or in relation to the accuracy or completeness of the information, statements, opinions or matters, express or implied, contained in, arising out of or derived from, or for omissions from, this presentation, including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom.

None of the Company or any of the other Limited Parties act, or are responsible, as a fiduciary to you, your directors, officers, employees, affiliates, partners, representatives, consultants, agents, advisers, securityholders, creditors or any other person. You and each of the Company and the other Limited Parties expressly disclaim any fiduciary relationship. The Company and the other Limited Parties are relying on you complying with this important notice and disclaimer and on the truth and accuracy of the representations, warranties, undertakings and acknowledgments given by you.

This presentation may contain certain forward-looking statements, forecasts, estimates, projections and comments about future events, including the Company's beliefs, assumptions and expectations about the performance of its businesses and certain strategic transactions and the recovery of domestic and global airline booking levels. Forward looking statements can generally be identified by the use of forward-looking words such as, "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "goals", "aims", "target" and other similar expressions. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. Forward looking statements involve inherent risks and uncertainties, both general and specific, and there is a risk that such predictions, forecasts, projections and other forward-looking statements will not be achieved. A number of important factors, both known and unknown, could cause the Company's actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements, and many of these factors are beyond the Company's control. As such, there can be no assurance that actual outcomes will not differ materially from these statements. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and their differences may be material. Any forward-looking statements are provided as a general guide only and should not be relied on as an indication or guarantee of future performance. As such, no undue reliance should be placed on any forward-looking statement, particularly in light of the current economic climate and the significant volatility, uncertainty and disruption caused by the aftereffects of COVID-19 pandemic and certain geopolitical tensions. Past performance is not necessarily a guide to future performance, and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of any forward-looking statements or other forecast. Nothing contained in this presentation, or any other information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of the Company. None of the Company or any other Limited Party makes any representation or warranty as to the accuracy of any forward-looking statements contained in this presentation. Forward looking statements speak only as at the date of this presentation, and the Limited Parties disclaim any obligations or undertakings to release any update of, or revisions to, any forward-looking statements in this presentation.

Financial information contained in this presentation (if any) is unaudited, unless otherwise stated, and is therefore subject to change. You should be aware that this presentation has been prepared at a time when the review of the financial information contained in the presentation has not been completed and, accordingly, the Company takes no responsibility for, and can provide no assurance as to the reliability of, any information relating to the financial condition and/or financial and operating performance of the Company. Recipients of this presentation are cautioned therefore to not place any reliance on the financial (or other) information included in the presentation. A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this presentation. All dollar values are in Australian dollars (A\$) unless otherwise stated.

Certain market and industry data (including industry forecasts, projections, market sizes, market shares and market positions) included in this presentation has been obtained from public filings, research, surveys or studies conducted by third parties, including industry and general publications, which has not been independently verified by the Company, as well as from the Company's own internal estimates and research. The Company cannot warrant or guarantee the adequacy, fairness, accuracy or completeness of such information. You should note that market data and statistics are inherently predictive and subject to uncertainty and not necessarily reflective of actual market conditions. There is no assurance that any of the industry or market forecasts, including management estimates, which are referred to in this presentation will be achieved. In addition, such data involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. In addition, while the Company believes its own estimates and research are reliable, such estimates and research have not been verified by any independent source.

This presentation may contain trademarks and trade names of third parties, which are the property of their respective owners. Third party trademarks and trade names used in this presentation belong to the relevant owners and use is not intended to represent sponsorship, approval or association by or with the Company.

AGENDA

1. Enlitic Overview
2. Laitek Acquisition
3. Enlitic Business Momentum
4. Key Industry Event


Enlitic Overview

WHAT WE DO

The delivery of Ensign 2.0 lays the foundations for expanding capabilities

ENLITIC CORE COMPETENCY

Illustrative Example



Tangible Benefit	Use Case	Description
Improve Radiologist Productivity	Hanging Protocols	Puts time back in the hands of the radiologist
	Dictation template	
	AI orchestration	
Billing Accuracy	Contrast detection	Identifies and prevents lost billing opportunities
	Anatomy detection	
Data Monetisation	Deidentification	Delivers commercial insights and facilitates the potential sale of highly valuable curated data
	Data Curation	
Operational Efficiencies	Scan times	Drives revenue opportunities via increased patient throughput and reduced admin
	Image orchestration	
H&S / Liability Mgmt	Dose monitoring	Tracks patient wellbeing / safety and reduces legal liability through correcting human errors
	Laterality conflicts	

NECESSITY FOR ENLITIC USE CASES

Ensign 2.0's use cases have the potential to deliver significant value to our clients

Improve Radiologist Productivity

Enlitic estimates that a medium sized health system can achieve an annual increase in revenues by up to c.\$1.2M p.a.¹

Inaccurate descriptions increase read times.

Ensign 2.0 corrects study and series descriptions to decrease study read time by ~30 seconds².

Identify Billing Discrepancies

Missing or erroneous intravenous contrast could be underbilled in the U.S. by c.\$2B p.a.

Incomplete and inaccurate data is one of the main causes of underbilling.

Ensign 2.0 reviews the imaging data to identify key procedure data discrepancies.

Data Value Realisation

Tempus AI generated c.\$169M from the licensing of data and other analytical services in oncology in FY23

Non-standardised data reduces efficiency and poses significant challenges for research

Ensign 2.0 standardises imaging data and increases data value.

Improve and Enhance Data Quality

15% of extremity studies have unclear laterality, exposing radiology in the U.S. to a potential annual liability of c.\$3.4B

Inaccurate laterality data increases risk and impacts care delivery.

Ensign 2.0 reviews the data to identify potential laterality conflicts.

Realise Operational Efficiencies

A 5-minute reduction in average MRI scan times is expected to yield \$250K per machine p.a.

Due to siloed, non-standardised data, healthcare organisations struggle to achieve cost savings.

Ensign 2.0's ability to standardise data helps them achieve it.

Healthcare generates 30% of the world's data and almost 90% of that healthcare data is Medical Imaging Data

(1) Management estimates

(2) Management estimates derived from real life client examples.

BALANCE SHEET STRENGTH

Successful capital raise partially fund acquisition of Laitek and provide a robust Balance Sheet

PLACEMENT



- A\$22,500,000 raised
- Issue price: A\$0.05 per security
- A\$100,000 contributed by Directors
- All resolutions approved at general meeting

SECURITY PURCHASE PLAN



- Date of closure: 6 November 2024
- Expected commitments: approx A\$800,000
- Issue price: A\$0.05 per security
- All resolutions approved at general meeting



OUTCOMES



- Provision of significant financial strength to the company
- Partial funding of acquisition of Laitek
- Remainder should be sufficient to fund ongoing operations through to cash flow breakeven

Laitek Acquisition

LAITEK ACQUISITION

A strong strategic fit for Enlitic



1

Increase commercialisation

Increase penetration of our products with clients



2

Add complementary products

Enhance our product offering with additive product segments



3

Add to or strengthen our technological advantage

Continue by strengthening and advancing our leading technology



4

Create value for securityholders


Generate attractive returns from acquisitions by extracting the benefits



ABOUT LAITEK

Tech-enabled healthcare data migration

Laitek offers contract-based **data migration services** to US customers on a re-occurring basis as well as ongoing software licensing.



¹ As at 2 September 2024

Key Recent Clients

OEM Partnership Model



Direct Customers



TECH ENABLED DATA MIGRATION

An essential component of the medical imaging ecosystem

TECH ENABLED DATA MIGRATION

THE PREMISE IS SIMPLE

The process of extracting, translating and loading archived medical imaging data from one source (legacy PACS) to another source (target PACS)

Reasons health systems typically undergo a migration

Internal Upgrades



Storage to cloud




Cost Savings



M&A Activity



THE REALITY: HIGHLY COMPLEX



Many millions of studies encompassing petabytes of data are needed to be moved



There is an extremely low margin of error and if performed incorrectly, may result in destruction of critical data



Meticulous management of migration timings is necessary otherwise the entire PACS can crash, severely impacting patient wellbeing



Extremely time consuming, often taking upwards of 12+ months to complete



The migration software can take 10+ years and millions of dollars to develop

STRATEGIC RATIONALE

The Proposed Acquisition of Laitek is expected to deliver on Enlitic's key objectives

1

Accelerates the value of our use cases

- Combined service offering gives Enlitic immediate access to 10+ years of historical data while entrenching Ensign 2.0
- Increased depth of data accelerates the value of our Use Cases for clients

2

Moving critical technology in-house

- Laitek's routing capability is an essential technology for Enlitic which it would otherwise have to outsource at high cost
- Ability to tailor the capability to suit the implementation of Ensign 2.0 more efficiently

3

Identification of highly convertible sales leads

- Established pipeline of migration contracts identifies Enlitic's high value sales leads
- Strategically positioned for the structural industry evolution towards cloud-based storage

4


Significant value creation for Enlitic's shareholders

- Compelling cost and commercial synergies evident given exceptionally comparable customer base
- Alignment exists in many aspects of the team structure and infrastructure

ENLITIC & LAITEK

Realising Value from Data

DATA	ACCESS	ASSURE	ACTIVATE	ACHIEVE
<p>Medical imaging data within & across sites is:</p> <ul style="list-style-type: none">• Locked Away,• Mixed Terminologies,• Unstructured, and• Proprietary <p>This results in poor clinical, operational, financial, & research outcomes.</p>	<p>Medical imaging, orders, data, and reports that are:</p> <ul style="list-style-type: none">• On Unstable Systems,• Complex,• Large Volume, and• Proprietary. <p>Laitek's AI-enabled platform and extensive expertise has the ability to unlock data.</p>	<p>Ensure common terminology for optimal care:</p> <ul style="list-style-type: none">• Curation,• Enrichment,• Semantic Translation, and• Standardization. <p>Ensign's unique CV & NLP AI gains a comprehensive understanding of data & automatically standardizes it.</p>	<p>Data access and refinement is foundational to driving:</p> <ul style="list-style-type: none">• Key Use Cases,• Data Analytics,• Data Intelligence, and• Data Literacy. <p>Supports Clinical, Operational & Financial Excellence.</p>	<p>Data refinement ensures everyone, & every IT system uses the correct data for:</p> <ul style="list-style-type: none">• Insights,• New Revenue,• Higher ROI, and• Better Outcomes. <p>Drive sustainable clinical, operational & financial goals.</p>



DATA ELEMENTS	MIGRATE, MOVE, DE-ID, CONVERT	STANDARDIZE DATA	WORKFLOWS	ROI
IncidentalF	←→	CT Brain NONCON	Simplify Display Protocols Configuration	Increase Efficiency
Queens - ^ELB	←→	CR Upper Limb <small>(Laterality conflicts identified in data)</small>	Identify Laterality Conflicts	Reduce Risk
CHR^Brian	Discover, Interrogate, Index, CV / NLP	CT Brain NONCON <small>(Body part, contrast use, etc., sent to billing)</small>	Capture New Billing / RCM Info	Maximize Billing
PCCS Area Proto Brain	←→	CT Brain NONCON	Accelerate Case Assignment	Operational Excellence

COMBINED BUSINESS PROGRESS

Combined Offering

- Provide AI Enabled Workflow and Healthcare Data Migration Solutions
- Enlitic plans to include Ensign 2.0 as part of data migration services, providing a differentiated and highly valued offering to drive market share growth

Integrated Offering

- Integration of Enlitic and Laitek's products into a fully comprehensive offering has started
- Roadmap set to deliver AI Enabled Migrations to OEM partners in 2025

Sales Synergies

- Enlitic and Laitek sales functions have been combined and cross-functional selling has started
- Sales team is actively selling the joint offerings

Cost Reductions

- Right sizing of the combined businesses has begun and new organizational structure rolled out
- On track with implementing cost savings synergies

Development Support

- Enlitic providing development and engineering to support Laitek and further improve the data migration tools
- Laitek's highly experienced implementation team to support Enlitic deployments

Enlitic Business Momentum

PIPELINE: ENSIGHT 2.0

We expect Ensign 2.0 to accelerate clients through the pipeline

Note: The below logos constitute only a select portion of Enlitic's current pipeline. There is no guarantee that these opportunities will progress to End User Licence Agreements or generate any revenue for Enlitic.

OEM INTEGRATIONS

PROOF OF CONCEPT (POC) / CONTRACTING¹



Ensign 2.0

ENHANCEMENTS
WORKFLOWS
CUSTOMIZATION



intelerad

FUJIFILM
Value from Innovation

PHILIPS
Healthcare



datafirst



POC SCOPING²



radiology partners



AGFA
HealthCare



medica


Massachusetts General Hospital
Founding Member, Mass General Brigham

(1) POC / Contracting are parties actively in Proof of Concepts with Enlitic's technology (i.e. deploying and testing it) or are engaged in discussions in respect of commercial contracting.
(2) POC scoping are clients in discussions to determine the POC testing frameworks and outcomes that the clients would like to see


ENLITIC GROWTH

Our expanded capabilities through Ensign 2.0 and Laitek have provided a springboard for growth


Total Contract Value¹




Direct Clients



Contracted ARR²



Channel Partners



Recent New Contracts



BAYER



PHILIPS

In partnership with:
Blackford



DMC

In partnership with:
Biotronics3D



newVue | AI



Unilabs




NHS
Royal National
Orthopaedic Hospital
NHS Trust



Northern Light Health

In partnership with:


Merge
by merative



esaote



OpenRad



TestDynamics



国立がん研究センター
National Cancer Center Japan

In partnership with:


CLAIRVO
TECHNOLOGIES



UltraRAD

(1) TCV = Total Contracted Value. Represents the total contracted minimum license revenue to be charged over the term (generally 3 years of contracts entered into with customers) of the contract plus ancillary revenue (as applicable)
(2) ARR = Annual Recurring Revenue. The total annual revenue to be generated from current contracts that Enlitic has with its customer base

Key Industry Event

INCREASING INDUSTRY PRESENCE

Enlitic will have a strong presence at RSNA 2024, the world's leading imaging conference



Radiological Society of North America Scientific Assembly & Annual Meeting

1-5 December 2024,
Chicago, Illinois

>41,000
people¹

78% of
attendees
have
purchasing
power²

Showcasing
the latest
products
and
innovations

Enlitic's capabilities will be showcased in multiple locations throughout the exhibit hall, including:

- RSNA's Radiology Reimagined AI Showcase
- Enlitic Booth 4365 South Hall
- Laitek Booth 7707 North Hall
- Blackford Booth Panel discussion
- 10 Enlitic Partners to attend RSNA, with locations to showcase our solutions with our partners

(1) RSNA reported attendance at 2023 Meeting was more than 41,000
(2) As reported by RSNA

Thank you
